Reverie Labs

Jonah Kallenbach co-founded Reverie Labs and serves as CEO. He studied computational biology at Harvard, where he developed the early machine learning models that became the company's predictive platform. Kallenbach leads overall strategy and technical direction from the Cambridge headquarters.

Reverie partners with pharma companies on active drug discovery programs, applying its machine learning platform to predict pharmacokinetic properties and binding affinity during lead optimization. The firm embeds its models directly into medicinal chemistry workflows rather than licensing standalone software. Specific partner names and deal structures are not publicly disclosed, though the company has indicated it pursues co-development arrangements in select cases.

Reverie concentrates on small-molecule oncology programs. Disclosed work includes kinase inhibitor design and targeted protein degrader campaigns. The firm's platform is optimized for multi-parameter prediction — ADMET properties, selectivity, and binding affinity — within chemical space relevant to cancer therapeutics.

Reverie operates as a technology-enabled drug discovery company, not a pure software vendor. Unlike AI platform companies that sell tools, Reverie participates directly in medicinal chemistry programs and generates proprietary training data from each engagement, which compounds the predictive accuracy of its models over time.

Reverie Labs was founded in 2016 and went through Y Combinator's Summer 2017 batch. The company raised venture funding from DCVC — a deep-tech focused venture firm — alongside other early-stage investors. Co-founders Jonah Kallenbach and Ankit Gupta built the initial platform around applying deep learning to predict drug candidate properties before molecules reached synthesis and assay testing.